RTW Venture Fund Limited Announcement of Share Issuance (0727M)
16 Septiembre 2021 - 11:47AM
UK Regulatory
TIDMRTW
RNS Number : 0727M
RTW Venture Fund Limited
16 September 2021
LEI: 549300Q7EXQQH6KF7Z84
16 September 2021
RTW Venture Fund Limited
(the "Company")
Announcement of Share Issuance
Further to publication of the Company's 31 August 2021 net asset
value, released on 15 September 2021, and taking into consideration
interim performance of the Company's portfolio in September 2021,
the Company confirms that it may issue new ordinary shares at a
price of US$1.92 / GBP1.39 per new ordinary share, reflecting a 4.9
per cent. premium to the 31 August 2021 net asset value.
The Company intends to issue new ordinary shares on this basis
until 17 September 2021. Investors wishing to participate in this
issuance should reflect their interest to
james.e.bouverat@jpmorgan.com, liam.macdonald-ragget@jpmorgan.com
and carrie.fox@jpmorgan.com at J.P. Morgan Cazenove.
For Further Enquiries
RTW Investments, LP +1 (646) 343 9280
Stephanie Sirota, Chief Business Officer
Alexandra Taracanova, PhD, Director of Investor Relations
Julia Enright, Senior Business Development Associate
J.P. Morgan Cazenove +44 (0)20 7742 4000
William Simmonds
Jeremie Birnbaum (Corporate Finance)
James Bouverat (Sales)
Liam MacDonald-Raggett (Sales)
Carrie Fox
Elysium Fund Management Limited +44 (0) 14 8181 0100
Joanna Duquemin Nicolle, Chief Executive Officer
Sadie Morrison, Managing Director
Morgan Stanley Fund Services USA LLC +1 (914) 225 8885
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment fund
focused on identifying transformative assets with high growth
potential across the biopharmaceutical and medical technology
sectors. Driven by a long-term approach to support innovative
businesses, RTW Venture Fund invests in companies developing
next-generation therapies and technologies that can significantly
improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a
leading healthcare-focused entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more
information.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOELFMFTMTIBBAB
(END) Dow Jones Newswires
September 16, 2021 12:47 ET (16:47 GMT)
Rtw Biotech Opportunities (LSE:RTWG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Rtw Biotech Opportunities (LSE:RTWG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024